amnesia, anxiety, benign intracranial hypertension, convulsions, delirium, dementia (characterized by deficits in memory retention, attention, concentration, mental speed and efficiency, and occupational performance), depression, dizziness, EEG abnormalities, emotional instability and irritability, euphoria, hallucinations, headache, impaired cognition, incidence of severe psychiatric symptoms, increased intracranial pressure with papilledema (pseudotumor cerebri) usually following discontinuation of treatment, increased motor activity, insomnia, ischemic neuropathy, long-term memory loss, mania, mood swings, neuritis, neuropathy, paresthesia, personality changes, psychiatric disorders including steroid psychoses or aggravation of pre-existing psychiatric conditions, restlessness, schizophrenia, verbal memory loss, vertigo, withdrawn behavior
Its not clear yet whether the FDA will approve menthol-flavored ENDS products
Rupasinghe HPA, Perera IJJUN, Sandaruwan RDC, Jayapala HPS, Bellanthudawa BKA, Tennakoon A (2025) Coastal beach ecosystems contaminated by marine litter: impact on coastal biodiversity, tourism, and environmental sustainability
The school "tool kit" was designed to encourage communication with campuses, especially during Red Ribbon Week
SPEAKER_03 24:46 Yeah